Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160271 | 0.90 | REN (0.54) | ALDH1A1OPRM1NPSR1LMNAREN | |
| SCHEMBL6433208 | 0.87 | ALDH1A1 (0.64) | ALDH1A1OPRM1NPSR1LMNAMEN1 | |
| SCHEMBL4167652 | 0.87 | TP53 (0.54) | ALDH1A1LMNARENMEN1KMT2A | |
| SCHEMBL13472619 | 0.85 | ALDH1A1 (0.54) | ALDH1A1OPRM1NPSR1LMNAREN | |
| SCHEMBL4162457 | 0.84 | LTB4R2 (0.59) | ALDH1A1LMNARENNPC1CNR2 | |
| SCHEMBL14224515 | 0.83 | HDAC1 (0.58) | ALDH1A1OPRM1NPSR1LMNAREN | |
| SCHEMBL4156966 | 0.83 | LTB4R2 (0.54) | ALDH1A1LMNANPC1CNR2 | |
| SCHEMBL28319972 | 0.82 | ALDH1A1 (0.56) | ALDH1A1OPRM1NPSR1LMNAREN | |
| SCHEMBL4165489 | 0.82 | CNR2 (0.56) | ALDH1A1LMNANPC1CNR2 | |
| SCHEMBL4168772 | 0.82 | CNR2 (0.56) | ALDH1A1LMNANPC1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | ALDH1A1 2505/4885OPRM1 819/4885NPSR1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.